189209-27-6

Basic information

• Product Name: O-(2-AMinoethyl)-O'-[2-(Boc-aMino)ethyl]tetraethylene Glycol
• Synonyms: t-boc-N-amido-PEG6-Amine;t-boc-N-amido-PEG5-Amine;t-boc-N-amido-PEG5-Azide;tert-Butyl (17-amino-3,6,9,12,15-pentaoxaheptadecyl)carbamate;Boc-N-amido-PEG5-Amine;Boc-N-amido-PEG5-Azide;O-(2-AMinoethyl)-O'-[2-(Boc-aMino)ethyl]tetraethylene Glycol;19-AMino-5,8,11,14,17-pentaoxa-2-azanonadecanoic Acid 1,1-DiMethylethyl Ester
• CAS NO: 189209-27-6
• Molecular Formula: C₁₇H₃₆N₂O₇
• Molecular Weight: 380.47694
• Product Categories: Aliphatics;Amines;Intermediates;Polyethyleneglycol Derivatives;PEGylation Reagents
• Mol File: 189209-27-6.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C(protect from light)
• Solubility: Soluble in Water, DMSO, DCM, DMF
• CAS DataBase Reference: O-(2-AMinoethyl)-O'-[2-(Boc-aMino)ethyl]tetraethylene Glycol(CAS DataBase Reference)
• NIST Chemistry Reference: O-(2-AMinoethyl)-O'-[2-(Boc-aMino)ethyl]tetraethylene Glycol(189209-27-6)
• EPA Substance Registry System: O-(2-AMinoethyl)-O'-[2-(Boc-aMino)ethyl]tetraethylene Glycol(189209-27-6)

Safety Data

• Hazardous Substances Data: 189209-27-6(Hazardous Substances Data)

Usage

Uses

Used in Biochip Technology:
O-(2-AMinoethyl)-O'-[2-(Boc-aMino)ethyl]tetraethylene Glycol is used as a key component in the preparation of novel biochip technology for the detection of explosives, specifically TNT. Its hydrophilic nature and reactive amino group contribute to the development of sensitive and selective detection methods.
Used in Chemical Synthesis:
In the field of chemical synthesis, O-(2-AMinoethyl)-O'-[2-(Boc-aMino)ethyl]tetraethylene Glycol serves as a reagent for the synthesis of chemical inducers of dimerization (CID). These CIDs are essential for identifying the protein targets of inhibitors that prevent the invasion of Toxoplasma gondii, a parasitic protozoa responsible for toxoplasmosis.
Used in Pharmaceutical Industry:
O-(2-AMinoethyl)-O'-[2-(Boc-aMino)ethyl]tetraethylene Glycol is used as a PEG linker for the development of drug conjugates and targeted therapies. The hydrophilic PEG spacer improves the solubility and pharmacokinetic properties of the resulting drug molecules, while the reactive amino group allows for the attachment of various drug payloads or targeting moieties.
Used in Material Science:
In material science, O-(2-AMinoethyl)-O'-[2-(Boc-aMino)ethyl]tetraethylene Glycol can be utilized as a building block for the synthesis of PEGylated polymers and copolymers with tailored properties. These materials can find applications in various fields, such as drug delivery, tissue engineering, and surface modification for improved biocompatibility.

Upstream product

• 911209-07-9 tert-butyl N-[2-[2-[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate 
• 331242-61-6 tert-butyl N-[2-[2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate 
• 430430-57-2 2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecane-13-yl methanesulfonate 
• 1186579-82-7 2-[2-[2-[2-[2-[2-(tert-butoxycarbonylamino)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl methanesulfonate 
• 6338-55-2 2-(2-(2-aminoethoxy)ethoxy)ethan-1-ol 
• 5197-62-6 2-[2-(chloroethoxy)ethoxy]ethanol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 86520-52-7 2-[2-(2-azidoethoxy)ethoxy]ethanol 
• 139115-92-7 tert-butyl 2-(2-(2-hydroxyethoxy)ethoxy)ethylcarbamate 
• 2615-15-8 pentaethylene glycol 
• 42749-28-0 toluene-4-sulfonic acid 2-[2-(2-{2-[2-(2-hydroxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethyl ester 
• 86770-69-6 17-azido-3,6,9,12,15-pentaoxaheptadecan-1-ol 
• 39160-70-8 3,6,9,12,15,18-hexaoxa-1-octadecyl amine 
• 1264015-76-0 2-{2-[2-(2-[2-(2-tert-butoxycarbonylaminoethoxy)ethoxy]ethoxy)ethoxy]ethoxy}ethyl p-tosylate 

Downstream Products

• 1186579-84-9 C₄₃H₅₃N₅O₁₁ 
• 1355027-79-0 tert-butyl [2-(2,2-dimethyl-4,24-dioxo-3,8,11,14,17,20-hexaoxa-5,23-diazahexacosan-26-yl)-4-{[(4-{[(2,6-dimethylphenyl)carbamoyl]amino}phenyl)acetyl]amino}phenoxy]acetate 
• 1355027-66-5 [2-(21-amino-3-oxo-7,10,13,16,19-pentaoxa-4-azahenicos-1-yl)-4-{[(4-{[(2,6-dimethylphenyl)carbamoyl]amino}phenyl)acetyl]amino}phenoxy]acetic acid trifluoroacetate 

Relevant articles and documents

COMPOSITIONS AND METHODS RELATED TO MOLECULAR CONJUGATION

The invention relates to activated Michael acceptor (AMA) compounds that can undergo conjugation with biomolecules containing Michael donor moieties, thereby providing plasma-stable antibody-drug conjugates (ADCs). Pharmaceutical compositions of the ADCs are disclosed as well. Also provided herein are a number of applications (e.g., therapeutic applications) in which the compositions are useful.

Modified methotrexate as well as preparation method and application thereof

The invention provides a modified methotrexate. According to the invention, a polyethylene glycol chain with adjustable length is introduced into methotrexate; and a maleimide group is introduced to the tail end of the polyethylene glycol linker, wherein the maleimide group can be directionally crosslinked with free sulfydryl of protein in the future, so that the steric hindrance of methotrexate is overcome, and the problem of non-directional selectivity of regions of two carboxyl groups is solved, thereby obtaining better crosslinking effect and crosslinking efficiency.

EXENATIDE MODIFIER AND USE THEREOF

Disclosed are an exenatide modifier for connecting the exenatide to a fatty chain with a carboxy in the terminus thereof by means of a hydrophilic connecting arm, and a use thereof in preparing drugs serving as a GLP-1 receptor agonist; a use in preparing drugs for preventing and/or treating diseases and/or symptoms associated with a low GLP-1 receptor activity; a use in preparing drugs for diseases and/or symptoms associated with glycometabolism; a use in preparing drugs for diabetes; a use in preparing drugs for fatty liver disease, and a use in preparing drugs for losing weight.

Solid-Phase-Based Synthesis of Ureidopyrimidinone-Peptide Conjugates for Supramolecular Biomaterials

Supramolecular polymers have shown to be powerful scaffolds for tissue engineering applications. Supramolecular biomaterials functionalized with ureidopyrimidinone (UPy) moieties, which dimerize via quadruple hydrogen-bond formation, are eminently suitable for this purpose. The conjugation of the UPy moiety to biologically active peptides ensures adequate integration into the supramolecular UPy polymer matrix. The structural complexity of UPy-peptide conjugates makes their synthesis challenging and until recently low yielding, thus restricted the access to structurally diverse derivatives. Here we report optimization studies of a convergent solid-phase based synthesis of UPy-modified peptides. The peptide moiety is synthesized using standard Fmoc solid-phase synthesis and the UPy fragment is introduced on the solid-phase simplifying the synthesis and purification of the final UPy-peptide conjugate. The convergent nature of the synthesis reduces the number of synthetic steps in the longest linear sequence compared to other synthetic approaches. We demonstrate the utility of the optimized route by synthesizing a diverse range of biologically active UPy-peptide bioconjugates in multimilligram scale for diverse biomaterial applications. 1 Introduction 2 Divergent Synthesis 3 Convergent Synthesis 4 UPy-Amine Strategy 5 UPy-Carboxylic Acid Strategy 6 Conclusion.

LDV peptidomimetics equipped with biotinylated spacer-arms: Synthesis and biological evaluation on CCRF-CEM cell line

The tripeptide Leu-Asp-Val (LDV) is known to bind α4β 1 integrin in leukemia cells. Here we have synthesized a LDV peptidomimetic equipped with a biotin-conjugated spacer-arm. Compound 9 acts as an inhibitor of the α4β1 integrin in an adhesion assay using fluorescently labeled, α4β 1 integrin-expressing leukemia CCRF-CEM cells. Furthermore, when bound to neutravidin-coated plates, compound 9 could capture CCRF-CEM cells. Such biotin-conjugated LDV peptidomimetic may thus represent a novel tool for biotechnological applications using avidin interaction for leukapheresis or leukemia cell targeting.

Synthesis and biological evaluation of functionalised tetrahydro-β- carboline analogues as inhibitors of Toxoplasma gondii invasion

Techniques for the identification of the protein target(s) of small molecules are proving very important following an increase in the use of phenotype-based screening in chemical biology and drug discovery. One approach, known as the yeast-3-hybrid approach, has shown considerable potential. A key factor in the success of this approach is the preparation of a complex molecule referred to as a chemical inducer of dimerisation (CID). The synthesis of two CIDs based on a bioactive tetrahydro-β-carboline core structure is reported and evidence presented that shows the CIDs are of utility in this approach. A series of chemo- and bioinformatic studies coupled with SAR development inspired the choice of CIDs.

Synthesis of methotrexate-containing heterodimeric molecules

The present invention relates to novel compositions of methotrexate-containing heterodimeric probe molecules, also known as chemical inducers of dimerization (CID), useful in three-hybrid assays. The invention further relates to synthesis of said compositions and their intermediates. Another aspect of the invention is a method for using the heterodimeric probe molecules described herein in drug screens to identify potential protein targets to a given ligand, optimize protein-ligand interactions, or identify potential ligands for a given protein target. In certain embodiments, the invention contemplates the synthesis of the following methotrexate-containing heterodimeric probe: